Company description

BIOCAD is an international, vertically integrated biotechnology company. It excels at full-cycle drug discovery and development, as well as commercial-scale manufacturing of therapeutic proteins for the treatment of various types of cancer and autoimmune disorders. This year, BIOCAD launched its first two drug products based on original monoclonal antibodies, netakimab (anti-IL17) and prolgolimab (anti-PD1). Both of these products will be available in the EU and China. A dozen more BIOCAD’s innovative molecules are at various stages of pre-clinical and clinical development. The company also continues to introduce high-quality mAbs biosimilars to the emerging markets. BIOCAD is open to potential collaborations that are synergistic with its marketing plans and robust R&D programs.

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Africa; Central/South America
Affiliated categories: Antibodies |Biopharmaceuticals (general category) |Biosimilars More

Upcoming events

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany Visit us at stand 80C65 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

9 oct 2018

CPhI Worldwide 2018

9 - 11 October 2018 Madrid, Spain We were at stand 9H72 See our Exhibitor Profile   See full Exhibitor List
24 oct 2017

CPhI Worldwide 2017

24 - 26 October 2017 Messe Frankfurt, Germany We were at stand 62B31 See our Exhibitor Profile   See full Exhibitor List

Contact information




View all contact information